DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statewide Immunization Information System Developer's Workshop

The National Immunization Program (NIP) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Statewide Immunization Information system (SIIS) Developer's Workshop.

Times and Dates: 8:30 a.m.–4 p.m., August 1, 1995; 8:30 a.m.–4 p.m., August 2, 1995; 8:30 a.m.–4 p.m., August 3, 1995.

Place: Omni Hotel at CNN Center, 100 CNN Center, Atlanta, Georgia 30335, telephone 404/659–0000, (Reservations 404/818–4300).

Status: The meeting will be open to the public, attendance limited only by space available. The meeting room will accommodate approximately 280 people.

Purpose: This workshop will focus on technical issues and guidelines related to the SIIS projects, and CDC's role in the SIIS technical support and implementation.

Matters To Be Discussed: Topics to be discussed will include: SIIS architecture and design; Record Exchange Interface; Gateway Interface Specification design; Data Communication Security; immunization history evaluation algorithms; patient de-duplication algorithms; programming confidentiality; vaccine code structure; Health Level 7 (HL7) data exchange standards; Information Network for Public Health Officials (INPHO); and Clinic Assessment Software Application (CASA).

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Donna Williams, Program Analyst, NIP, CDC, 1600 Clifton Road, NE, (E–62), Atlanta, Georgia 30333, telephone 404/639–8243.

Dated: May 31, 1995.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–13780 Filed 6–5–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Psychopharmacologic Drugs Advisory Committee

Date, time, and place. July 24 and 25, l995, 8:30 a.m., Gaithersburg Hilton, Grand Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, July 24, l995, 8:30 a.m. to 5 p.m.; open committee discussion, July 25, l995, 8:30 a.m. to 5 p.m.; open public hearing, 5 p.m. to 6 p.m., unless public participation does not last that long; Michael A. Bernstein, Center for Drug Evaluation and Research (HFD–120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–5521, or FDA Advisory Committee Information Hotline, l–800–741–8138 (301–443–0572 in the Washington, DC area), Psychopharmacologic Drugs Advisory Committee, code 12544.

General function of committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the practice of psychiatry and related fields.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before July 17, l995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On July 24 and 25, l995, the committee will discuss issues in the design and conduct of studies involving antipsychotic drugs.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: May 25, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–13752 Filed 6–5–95; 8:45 am]

BILLING CODE 4160–01–F

Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HF (Food and Drug Administration) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970 and 56 FR 29484, June 27, 1991, as amended most recently in pertinent parts at 55 FR 12283, April 2, 1990) is amended to reflect the following reorganization in the Food and Drug Administration (FDA).

The Office of Biotechnology, Office of Operations, is being abolished. The biotechnology industry has evolved to the point where the functions of this office are more appropriately performed by FDA's centers. The office's industry liaison activities will be performed by FDA's Office of External Affairs under its existing liaison functions.

Under section HF–B, Organization:

1. Delete subparagraph Office of Biotechnology (HFA–H), Office of Operations (HFA9), in its entirety.

Prior Delegations of Authority. Pending further delegations, directives, or orders by the Commissioner of Food and Drugs, all delegations of authority to positions of the affected organizations in effect prior to this date shall continue in effect in them or their successors.

Dated: May 17, 1995.

David A. Kessler,

Commissioner of Food and Drugs.

[FR Doc. 95–13710 Filed 6–5–95; 8:45 am]

BILLING CODE 4160–01–M

Health Resources and Services Administration

Advisory Council; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of June 1995:

Name: Council on Graduate Medical Education Medical Licensure Subgroup.

Time: June 23, 1995, 8:30 a.m.–4:00 p.m.

Place: Crystal Gateway Marriott, 1700 Jefferson Davis Highway, Arlington, VA 22202.

Open for entire meeting.

Purpose: Review the operations of the American Medical Association's National Credentials Verification System and recommend if appropriate, an alternative credentials verification system or process for physicians that assures nondiscriminatory policies and practices in the operation of the system.

Review the policies and practices of State Medical Boards in licensing international medical graduates and U.S. medical graduates, and determine the effects of such policies and practices.

Report and make recommendations to Congress, the Secretary of Health and Human Services and the Council on Graduate Medical Education regarding the finding of the subgroup.

Agenda: The agenda for the third meeting of the Council on Graduate Medical Education Medical Licensure Subgroup includes a review of the results of the pilot test of the proposed questionnaire for the survey of selected State medical boards. Presentation will be made by the Educational Commission for Foreign Medical Graduates (ECFMG) and the Federation of State Medical Boards (FSMB) regarding their operations and their views on the development of a private sector national credentials verification system.

Anyone requiring information regarding the meeting should contact Stanford Bastacky, D.M.D., M.H.S.A., telephone (301) 443–6785; Division of Medicine, Bureau of Health Professions, Health Resources and Services Administration, Room 9A–27, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Agenda Items are subject to change as priorities dictate.

Dated: May 31, 1995.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 95–13709 Filed 6–5–95; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting of the Sickle Cell Disease Advisory Committee

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Sickle Cell Disease Advisory Committee, National Heart, Lung, and Blood Institute, June 16, 1995. This meeting will be held at the National Institutes of Health, Federal Building, Conference Room B1–19, 7550 Wisconsin Avenue, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 9:00 a.m. to adjournment, to discuss recommendations on the implementation and evaluation of the Sickle Cell Disease Program. Attendance by the public will be limited to space available.

Ms. Terry Long, Chief, Communications and Public Information Branch, National Heart, Lung, and Blood Institute, Building 31, Room 4A21, Bethesda, Maryland 20892, (301) 496–4236, will provide a summary of the meeting and a roster of the committee members upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

Dr. Clarice D. Reid, Executive Secretary, Sickle Cell Disease Advisory Committee, Division of Blood Diseases and Resources, NHLBI, Two Rockledge Building, Suite 10160, 6701 Rockledge Drive, Bethesda, Maryland 20892, (301) 435–0080, will furnish substantive program information.

This notice is being published less than fifteen days prior to the meeting due to the conflict of schedules of committee members.

(Catalog of Federal Domestic Assistance Program No. 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: May 30, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–13712 Filed 6–5–95; 8:45 am]

BILLING CODE 4140–01–M